Venofer (iron sucrose injection) is indicated for the management of iron deficiency anemia (IDA), which is a condition characterized by a shortage of iron necessary to produce healthy red blood cells. The medication may help manage symptoms commonly associated with IDA, such as fatigue, weakness, and reduced physical capacity. The aim is to support the body in restoring appropriate iron levels.

Main Uses and Therapeutic Domains

Venofer is used for patients diagnosed with iron deficiency anemia in specific clinical situations where oral iron supplements are not effective or cannot be used. The brief listing of approved indications includes treating IDA in patients with hemodialysis-dependent chronic kidney disease (HDD-CKD), those with non-dialysis-dependent chronic kidney disease (NDD-CKD), and patients with IDA receiving supplemental erythropoietin therapy.

“Replenishment of iron stores may support an improvement in the quality of life for patients suffering from chronic iron deficiency anemia.”

The benefit for the patient is the replenishment of iron stores and a potential rise in hemoglobin levels, which assists in providing relief from chronic anemia-related symptoms. This therapeutic approach is consistent with established clinical management.

Quick Fact: Relief for Anemia-Related Fatigue

Who can and cannot use Venofer 100mg/5ml?

The eligibility for Venofer (iron sucrose) is strictly defined by government regulatory documents, focusing on a specific disease context and clear exclusions.

---

Eligibility Scope

Populations for whom use is allowed: Venofer is indicated for adults and pediatric patients 2 years of age and older who have Iron Deficiency Anemia (IDA) associated with Chronic Kidney Disease (CKD). This includes patients who are hemodialysis-dependent, non-dialysis-dependent, or peritoneal dialysis-dependent.

Populations for whom use is contraindicated: The medicine must not be used if a patient has a known hypersensitivity to the drug or its components. It is also strictly contraindicated if there is evidence of iron overload or if the patient's anemia is due to a cause other than iron deficiency.

Age-related eligibility rules: Safety and efficacy are not established for children less than 2 years of age. Older adults may require cautious administration, reflecting the possibility of decreased hepatic, renal, or cardiac function.

Pregnancy and lactation eligibility status: Use during the first trimester of pregnancy is generally not recommended. In the second and third trimesters, use is conditional and requires a careful assessment due to the documented risk of reactions that may cause fetal bradycardia. Caution is advised during lactation.

Interactions with other medicines and products

Official regulatory information for Venofer (iron sucrose injection) documents a highly specific and narrow interaction profile, primarily concerning co-administered iron preparations and administration constraints.

Documented Pharmacokinetic Interaction

The primary interaction involves Oral Iron Preparations. The regulatory documents confirm that the intravenous administration of Venofer may lead to a reduction in the absorption of concurrently administered oral iron supplements. This is classified as a pharmacokinetic interaction.

To prevent this interference and ensure appropriate iron uptake, a mandatory timing separation is required. Oral iron therapy must be deferred and initiated a minimum of 5 days following the last injection of Venofer.

---

Procedural and Physical Incompatibility Restrictions

In-Solution Incompatibility: A strict procedural constraint prohibits the mixing of Venofer with any other medicinal product or solution, including parenteral nutrition solutions, in the same infusion container. Venofer must only be diluted in sterile 0.9% sodium chloride solution before administration, as co-administration with other substances carries a high risk of physical precipitation.

No clinically significant interactions involving metabolic enzyme systems (such as CYP450 enzymes), specific drug transporters, food, alcohol, or standard herbal products are documented in the official regulatory sections for Venofer.

Fe^3+ Delivery via the Reticuloendothelial System (RES)

Venofer (iron sucrose) is a complex designed for direct intravenous delivery of elemental ferric iron ( Fe^3+). Upon injection, the stable iron complex is primarily taken up by macrophages within the reticuloendothelial system (spleen, liver, bone marrow), bypassing the initial digestive absorption process. Within these cells, the complex is dissociated, and the released iron is exported into the plasma. This process facilitates the mobilization of iron for distribution into the plasma iron pool.

---

Targeted Iron Transport and Erythroid Uptake

The elemental ferric iron ( Fe^3+) released into the plasma binds to the transport protein transferrin. This transferrin-iron complex carries the iron to sites of utilization, predominantly the bone marrow. Here, erythroid precursor cells internalize the complex via transferrin receptors, which provides iron substrate for the subsequent steps of red blood cell formation.

---

Heme Synthesis and Hemoglobin Cascade Support

The internalized iron is channeled into the mitochondria of the erythroid cells and incorporated into the protoporphyrin ring to form heme. This supports the structural synthesis of hemoglobin molecules. This mechanistic domain supports the increase in the iron content of red blood cells, impacting the functional capacity for oxygen transport.

Venofer (iron sucrose injection) is administered intravenously (IV) only, delivered as either a slow IV injection or a controlled infusion. This parenteral route ensures the iron is delivered directly into the bloodstream. The standard adult treatment goal is a total cumulative dose of 1000 mg elemental iron, although the specific dosing schedule and frequency depend on the patient's Chronic Kidney Disease (CKD) indication.

For adult patients with Hemodialysis-Dependent CKD (HDD-CKD), the typical administration is a 100 mg dose given during consecutive hemodialysis sessions. Patients with Non-Dialysis Dependent CKD (NDD-CKD) usually receive 200 mg doses over five occasions across a 14-day period.

Proper preparation is essential. The solution must be diluted only in 0.9% sodium chloride to achieve a concentration of 1 to 2 mg/mL elemental iron. The infusion rate is highly controlled: for example, 100 mg or 200 mg doses must be infused over at least 15 minutes. For pediatric patients aged two years and older, a weight-based dose, not to exceed 100 mg, is used for maintenance treatment, which is typically administered over a 12-week duration. Following administration, serum iron measurements should not be performed for a minimum of 48 hours to ensure accurate results.

Venofer 100mg/5ml: Recent Clinical Evidence

---

Evidence for Use in Iron Deficiency Anemia (IDA) and Chronic Kidney Disease (CKD)

Research has primarily explored the study of Iron Sucrose in patients with Iron Deficiency Anemia (IDA) that often occurs in patients with Chronic Kidney Disease (CKD). The evidence base is structured around Randomized Controlled Trials (RCTs) and meta-analyses that compared the intravenous administration to other therapeutic approaches. These studies were applied in research contexts involving patients across the CKD spectrum, including those undergoing dialysis and those who were not yet dialysis-dependent. Researchers examined changes in Hemoglobin concentration and monitored iron storage biomarkers such as Ferritin and Transferrin Saturation. Findings describe patterns observed in the studies related to measurable shifts of these iron and blood markers. While the initial observation phase has been well-studied, long-term effects are not fully established and there is limited information for long-term outcomes beyond one to two years.

---

Research on Iron Deficiency in Other Clinical Contexts

Research has also explored the use of Iron Sucrose in other clinical situations where iron deficiency was evaluated alongside conditions marked by functional limitations or systemic imbalance. For patients with Chronic Heart Failure (CHF) and concurrent iron deficiency, studies evaluated whether Iron Sucrose administration was associated with changes in patient-reported outcomes, measured functional outcomes, and hospitalization rates. For patients with Inflammatory Bowel Disease (IBD), RCTs compared intravenous Iron Sucrose to oral iron, with findings indicating that patterns related to the measured shifts in iron biomarkers were different when comparing the intravenous route versus the oral route in this specific group.

---

Long-Term Evidence and Special Patient Groups

A key area of inquiry is the durability of the response studied. The available research monitored patient responses over defined time intervals, but the follow-up durations were limited in many studies. Research so far indicates that specific, extended long-term outcomes are not fully established.

Research describes the evaluation of Iron Sucrose in pediatric patients (children aged 2 years and older) who have CKD, exploring how symptoms change over time and often monitoring shifts in iron levels. However, data for certain groups remain insufficient, particularly for children younger than 2 years of age.

---

What Remains Uncertain in the Research Landscape

It is important to understand the known gaps in the evidence. Research is ongoing but certain areas still lack definitive information. The evidence quality varies across studies, and many of the findings describe group patterns, not personal outcomes. For clinical contexts beyond CKD, the evidence is sometimes derived from trials where the sample sizes were modest. Furthermore, long-term comparative evidence is limited when assessing Iron Sucrose against other approaches for outcomes such as major health events.

Key Studies & References NIH MedlinePlus Drug Information for Iron Sucrose Injection

Common questions about Venofer 100mg/5ml (FAQ)

Q: How long do the effects of a Venofer infusion last?

Official information describes a full course of treatment, such as the typical cumulative dose of 1000 mg, intended to replenish iron stores. The prescribing information does not define a specific duration of the therapeutic effect.

Treatment may be repeated if blood tests show that iron deficiency has returned.

---

Q: What are the most common things people feel during a Venofer treatment?

Regulatory documents state that common reactions reported during or shortly after the infusion include physical sensations such as taste perversion, nausea or vomiting, headache, and dizziness.

---

Q: Can Venofer cause problems with my blood pressure?

Yes, official safety information documents that Venofer can cause a significant drop in blood pressure, known as hypotension. Regulatory warnings indicate patient monitoring is required during and immediately following the administration.

In some reports involving children, a rise in blood pressure (hypertension) has also been observed.

---

Q: Is it true that Venofer can cause a change in taste?

Yes, a change in taste is an officially documented common side effect reported in clinical data. This change in taste is officially termed 'taste perversion (dysgeusia)'.

---

Q: Can Venofer be used during pregnancy?

Use during pregnancy requires a careful assessment because the potential benefit must justify the risk to the fetus.

In the second and third trimesters, severe allergic reactions from the medicine may be associated with a slowing of the baby’s heart rate (fetal bradycardia).

---

Q: Why does Venofer sometimes cause flushing or warmth?

Official information lists flushing (a sudden feeling of warmth or redness) as a symptom that can be associated with serious allergic reactions or hypersensitivity events.

Patients are closely monitored during the infusion for any signs of these reactions.

---

Q: Can Venofer cause discoloration or staining where the needle went in?

Yes, injection site discoloration has been reported. This usually happens after extravasation, which is when the medicine leaks out of the vein into the surrounding tissue during the infusion.

---

Q: Can Venofer be used if I am already taking oral iron pills?

Venofer can interact with oral iron by reducing the amount of iron the body absorbs from the pills. Regulatory documents state that oral iron therapy must be deferred and resumed only after a specific period following the last Venofer injection.

Oral iron should only be restarted a minimum of 5 days following the final injection of Venofer.

---

Q: Do I need to do anything special to prepare for a Venofer infusion?

Official prescribing information requires periodic monitoring of blood markers, including serum ferritin and transferrin saturation.

Additionally, for patients undergoing hemodialysis for kidney disease, the administration condition specified is that the medicine must be given early during the dialysis session.

---

Q: Is Venofer used for low iron levels even if I don't have anemia?

No, Venofer is specifically indicated for the treatment of Iron Deficiency Anemia (IDA). Official documents state the medicine must not be used if a patient's anemia is caused by something other than iron deficiency.

---

Q: Is it common to feel dizzy or lightheaded right after the infusion?

Dizziness is a commonly reported adverse reaction. This, along with a drop in blood pressure (hypotension), is known to occur during the infusion or in the 30 minutes immediately following administration.

---

Q: Can Venofer affect the results of other blood tests I get?

Venofer administration may impact the immediate results of iron marker tests. Official guidance specifies that blood tests for serum iron measurements should not be performed for at least 48 hours after administration to ensure the results are accurate.

---

Q: What is the total number of Venofer doses usually recommended?

The total number of doses depends on the specific condition being treated, but the total cumulative dose for a treatment course is typically 1000 mg.

This usually corresponds to 10 doses of 100 mg for patients on hemodialysis, or 5 doses of 200 mg for patients with Chronic Kidney Disease who are not on dialysis.

---

Q: Do I have to stay in the clinic for a long time after getting Venofer?

Yes, regulatory documents require that patients be monitored for signs of severe allergic reactions and low blood pressure during and for at least 30 minutes following the completion of the infusion, or until they are stable.

---

Q: Is there a maximum number of times a person can receive Venofer?

There is no maximum lifetime limit specified in the prescribing information. The drug label states that a course of Venofer treatment may be repeated if iron deficiency reoccurs over time.

---

Q: How does Venofer specifically help people with kidney disease?

Venofer is officially indicated to treat Iron Deficiency Anemia (IDA) that is specifically associated with Chronic Kidney Disease (CKD). The medicine’s official indication defines its use for this specific patient population.

---

Q: Are there any official warnings about driving after receiving Venofer?

Because Venofer can cause side effects like dizziness and may affect alertness or coordination, regulatory patient information advises that activities requiring alertness should be avoided until an individual knows how the medicine affects them.

---

Q: Are there any reported long-term effects of using Venofer?

A documented risk associated with excessive or long-term, cumulative exposure is Iron Overload, also known as Hemosiderosis.

Patients receiving Venofer require periodic monitoring of iron levels and blood markers to help evaluate this outcome.

---

Q: Does Venofer interact with any herbal supplements?

Official regulatory documents do not document clinically significant interactions involving standard herbal products.

---

Q: Do studies support the use of Venofer in treating restless legs syndrome?

Research has explored the use of intravenous iron sucrose in patients with Restless Legs Syndrome (RLS) in a study context. However, official prescribing information does not include an indication for Restless Legs Syndrome.

---

Q: Can Venofer change my weight?

Clinical data has reported certain adverse events including peripheral edema (which is swelling or fluid retention) and, in some cases, unusual weight gain or loss.

---

Q: What precautions are taken to prevent side effects during the infusion?

Precautions include administering the dose over a minimum defined time period (e.g., at least 15 minutes) to avoid rapid administration.

Patients are also continuously monitored for signs of severe hypersensitivity and low blood pressure during and after the infusion.

Storage and Disposal of Venofer (Iron Sucrose Injection)

Unopened Venofer 100 mg/5 mL vials must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). It is essential that the product is not frozen and is stored in the original carton for protection. Keep the medicine out of the sight and reach of children.

Since Venofer is a preservative-free, single-dose solution, it should be used immediately after opening or dilution. Any unused portion remaining in the vial must be discarded promptly. Disposal of the unused product and all associated waste material must be carried out in accordance with local requirements for pharmaceutical waste.